Company intelligence / Profile preview

ViewPoint Therapeutics

San Francisco, California, United Statestherisefund.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ViewPoint Therapeutics developed alpha-crystallin aggregation inhibitors that have demonstrated the ability to reverse age-related cataracts in primates. The company was acquired by Visus Therapeutics in September 2022, with lead candidate selection anticipated in Q1 2023.

Therapeutic areas: Ophthalmology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

VP1-001

Pre-clinical

Indications: Cataracts, Presbyopia

Beyond the preview

Go deeper on ViewPoint Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViewPoint Therapeutics.

Explore the full profile